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Summary
Salmonella spp. require the ADP-ribosyltransferase
activity of the SpvB protein for intracellular growth
and systemic virulence. SpvB covalently modifies
actin, causing cytoskeletal disruption and apoptosis.
We report here the crystal structure of the catalytic
domain of SpvB, and we show by mass spectrometric
analysis that SpvBmodifies actin at Arg177, inhibiting
its ATPase activity. We also describe two crystal
structures of SpvB-modified, polymerization-deficient
actin. These structures reveal that ADP-ribosylation
does not lead to dramatic conformational changes in
actin, suggesting a model in which this large family
of toxins inhibits actin polymerization primarily
through steric disruption of intrafilament contacts.
Introduction
Salmonella spp. cause billions of human and agricultural
infections each year, leading to over three million human
deaths due to typhoid fever alone (Pang et al., 1995). The
spread of multidrug-resistant strains of Salmonella and
biosecurity concerns have recently focused more atten-
tion on this widespread pathogen (Angulo et al., 2000;
Cohen and Tauxe, 1986; Holmberg et al., 1984; Tacket
et al., 1985; Torok et al., 1997).Salmonella species utilize
two virulence-associated type III protein secretion sys-
tems (contained in the pathogenicity islands SPI-1 and
SPI-2) to inject virulence factors into host cells (Galan,
2001; Hansen-Wester and Hensel, 2001). SPI-1 func-
tions in the early stages of infection, inducing bacterial
uptake into nonphagocytic cells of the intestine (Galan
and Zhou, 2000). SPI-2 is involved subsequently in sys-
temic infection, allowing the bacteria to form a replica-
tive niche (the Salmonella containing vacuole, or SCV)
inside host cells and to colonize tissues beyond the
intestine (Hensel, 2000; Waterman and Holden, 2003).
Intracellular replication of several strains of Salmo-
nella in human and animal cell lines, as well as systemic
infection in animal models, requires the spv virulence
locus (plasmid or chromosomally located) and, in partic-
ular, the SpvB gene (Caldwell and Gulig, 1991; Libby
*Correspondence: stebbins@rockefeller.edu
3 Present address: Research and Development, Boehringer Ingel-
heim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, Connecti-
cut 06877.et al., 2002; Matsui et al., 2001). Although controversy
exists regarding whether SpvB is delivered via an
SPI-2-dependent translocation process (Browne et al.,
2002; Gotoh et al., 2003; Guiney and Lesnick, 2005),
this virulence factor exerts its function subsequent to
the actin reorganizing effects of both SPI-1 invasion-
associated effectors and those of the SPI-2 SCV-related
effectors (Guiney and Lesnick, 2005). Expressed alone in
mammalian cells or delivered by pathogenic bacteria,
SpvB disrupts the host cell cytoskeleton, culminating
in a cell death with many features of apoptosis (Browne
et al., 2002). It has been hypothesized that this apoptotic
death may facilitate pathogen spread to fresh cells
through autophagy (Guiney and Lesnick, 2005). Its im-
portant role in virulence makes SpvB an attractive target
for antibacterial development.
Several studies have shown that SpvB possesses ac-
tive site similarities to the large toxin family of mono-
ADP-ribosyltransferases (ATRs) that covalently transfer
ADP-ribose (ADPR) from nicotinamide adenine dinucle-
otide (NAD) to host proteins in order to modify their ac-
tivity (Lesnick et al., 2001). SpvB was recently shown to
ADP-ribosylate actin, and thereby to inhibit the polymer-
ization of this central cytoskeletal protein (Tezcan-
Merdol et al., 2001), placing it in a subclass of ATRs
targeting actin directly and indirectly, which includes
Clostridium botulinum C2 (iota toxin), Bacillus cerus
vegetative insecticidal protein (VIP2), C. perfringes iota
toxin, C. spiroforme toxin, and C. difficile toxin (Barbieri
et al., 2002; Barth et al., 2004; Han and Tainer, 2002;
Pallen et al., 2001).
Mono-ADP-ribosylation occurs in eukaryotic cells in
conjunction with ADP-ribosylhydrolases to modulate
the activity of proteins, and it represents a relatively
poorly characterized biochemical regulatory process
affecting signal transduction and metabolism (Corda
and Di Girolamo, 2003). A large number of bacteria use
ATRs as cellular toxins to induce irreversible changes
through modifications that cannot be removed by host
enzymes (Pallen et al., 2001). We have examined SpvB
biochemically and through X-ray crystallography in
order to understand its biological activity. We also pres-
ent studies of its host target protein, actin, identifying
the site of ADP-ribosylation and determining crystal
structures of SpvB-treated actin. These studies have
led us to a model for the mechanism of filament disrup-
tion caused by SpvB within the host cell.
Results and Discussion
A minimal ATR domain of SpvB was defined by limited
proteolysis (spanning residues 390–591), and its activity
was verified in actin polymerization assays (Figure 1 and
Experimental Procedures). Nucleotide-free and NADH
(nonhydrolyzable form of NAD) structures were deter-
mined to 1.5 A˚ and 1.9 A˚ resolution, respectively (Figures
1 and 2A–2C; Table 1). These structures reveal that the
SpvB ATR domain adopts the canonical fold of this
broad toxin family, consisting of an a/b fold with two
nearly perpendicular b sheets juxtaposed at a helical
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1220Figure 1. Delineation and Structural Determination of the SpvB ADR Domain
(A) Limited proteolysis of a soluble SpvB C-terminal domain construct (370–591) reveals a banding pattern of N-terminal truncations. N-terminal
sequencing (Edman degradation) revealed that the protease had cut at several close locations as noted (*). The smallest stable fragment is of
a construct ofw22 kDa (390–591).
(B) Polymerization of G-actin in high-salt buffer, in the presence and absence of SpvB (390–591), was undertaken with pyrene-labeled actin, and
the extent of polymerization was measured by an increase in fluorescence, shown in relative fluorescence units (RFU). Novobiocin, an inhibitor of
mono-ADP-ribosyltransferases, was used to test for inhibition of SpvB activity (Experimental Procedures).
(C) Electron density of the SpvB-NADH complex crystal structure showing a 2Fo 2 Fc map contoured at 1.0s.domain, and aligns best to VIP2 and C. botulinum C3
with root-mean-square deviations (rmsds) in the Ca po-
sitions of 2.4 A˚ and 2.7 A˚ over 140 residues (with Z
scores of 13.4 and 12.4, respectively; Holm and Sander,
1993) (Figures 2A and 3A). The key active site residues,
SpvB Arg471 and Glu538, are located in very similar po-
sitions to homologous residues in a subclass of ATRs,
including VIP2 and C3, that make critical contacts with
NAD by using an arginine instead of a histidine (the his-
tidine contact is found in the diphtheria ATR toxin family)
(Han et al., 1999, 2001). The SpvB ATR domain differs
from the other actin targeting enzymes (and all ATRs
known) by a 30 amino acid insertion in the helical subdo-
main (SpvB residues 415–445) (Figure 2) as well as by its
molecular surface (Figure 3B).
The cocrystal structure of the SpvB ATR domain with
NADH reveals that SpvB binds NAD in a manner similar
to VIP2 and C3 (Figure 3). Overall, SpvB, like VIP2,
makes a smaller number of contacts to the cofactor
than does C3. Like C3 and VIP2, SpvB uses an arginine
residue (Arg414) to interact with phosphate oxygen
atoms of NADH (Figure 3C). The active site catalytic res-
idues of SpvB, Arg471 and Glu538, also make contacts
to the ribose and phosphate oxygen atoms, as do ho-
mologous residues in the other ATR toxins. These key
similarities indicate that SpvB will function enzymati-
cally in a manner very similar to previously described
members of the ATR family.
Several actin targeting ATRs have been character-
ized, and in two cases the site of modification has
been mapped to Arg177 (Vandekerckhove et al., 1987,1988). Mechanistic models for other enzymes, such as
VIP2, have been published with this residue as the as-
sumed target (Han et al., 2001). Using mass spectromet-
ric analyses, we show that actin, both muscle and non-
muscle actin, is mono-ADP-ribosylated by SpvB, and
that, indeed, this modification is at Arg177 (Figure 4; Ta-
bles S1–S4 in the Supplemental Data available with this
article online). Intact molecular weight analysis of the
unmodified and SpvB-modified actin produced molecu-
lar weights differing byw544 Da, consistent with the ad-
dition of an ADPR group (541 Da). Trypsin digestion and
subsequent LC/FTMS analysis (combined liquid chro-
matography and Fourier transform mass spectroscopy)
of the ADPR-actin was used to identify the site of mod-
ification. Since peptides with an ADPR-arginine residue
at the C-terminal end are not susceptible to tryptic
cleavage (Zhou et al., 1996), an SpvB-modified peptide
should contain an (unmodified) arginine cut at the C
terminus and an ADPR-arginine within the interior
sequence of the peptide. Automated analysis of the
accurate mass (5 ppm window) data acquired in this
experiment showed the presence of peptides that cover
93% of the sequence (Figure 4; Tables S1–S4). Further
automated analysis of the LC/FTMS data was per-
formed by searching the data set for all possible tryptic
fragments, with up to two missed cleavages, with an ad-
ditional mass of 541.0611 Da, which corresponds to
ADP-ribosylation. This procedure identified a tryptic
peptide spanning residues 148–183 containing ADPR,
MW = 4363.0259 Da (theory) and MW = 4363.0280 Da
(observed). Subsequent LC/FT MS/MS analysis of this
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1221Figure 2. Crystal Structure of the Salmonella Virulence Factor SpvB
(A) Cocrystal structure of the SpvB and NADH shown as a ribbon diagram; NADH is shown as an atomic ‘‘ball-and’stick’’ model. The conserved
ADPR fold is shown in yellow, and the insertion specific for SpvB is highlighted in red. Secondary structural elements (‘‘H’’ for a helix, ‘‘b’’ for
b strands) are shown and numbered by succession.
(B) The secondary structure and sequence of SpvB are shown. Red dots indicate residues making contacts with NAD. The red ‘‘A’’ and ‘‘B’’ refer
to b strands that are part of the first or second b sheet in the structure, respectively. Yellow ‘‘bs’’ indicate b turns.
(C) Topology diagram with secondary structure labeled. Red indicates the insertion region.component verified the sequence and showed the pres-
ence of fragments indicative of the ADPR addition. The
only arginine residue within this sequence is Arg177
(discounting Arg183, which is the C-terminal residueand the site of tryptic digest). These results are consis-
tent with recently published data with the actin homo-
log, Act88F (Drosophila indirect flight muscle protein),
in which the mutant of Act88F, Arg177Gln, showedTable 1. SpvB Data Collection, Phasing, and Refinement Statistics
Native (Single Crystal) NADH (Single Crystal) SeMet (Single Crystal)
Data Collection
Space group P3221 P3221 P3221
Cell dimensions
a, b, c (A˚) 55.6, 55.6, 143.6 55.6, 55.6, 143.6 55.7, 55.7, 143.9
a, b, g () 90, 90, 120 90, 90, 120 90, 90, 120
Wavelength 0.979 0.979 0.979
Resolution (A˚) 50.0–1.48 30.0–1.90 30.0–2.0
Rsym (%) 8.1 (33.4) 4.0 (36.7) 4.9(38.8)
I/sI 39.9 (2.1) 39.2 (3.9) 36.3 (3.7)
Completeness (%) 94.3 (62.0) 99.7 (100.0) 98.2 (81.7)
Refinement Mean Figure of Merit for Phasing SAD
Resolution (A˚) 48.1–1.50 30.0–1.90 SOLVE: 0.47 (0.39)
Number of reflections 39,071 19,881 RESOLVE: 0.74 (0.54)
Rwork/Rfree (%) 15.6/20.3 19.4/23.5
Mean B factor 21.6 30.1
Rms deviations
Bond lengths (A˚) 0.020 0.021
Bond angles () 1.700 1.865
Rsym =
P
h
P
ijIh,i 2 Ihj/
P
h
P
i Ih,i, for the intensity (I) of i observations of reflection h. Values in parentheses are for the high-resolution shell.
R =
PjFP 2 Fcj/
P
FP; FP is the experimental structure factor, and Fc is the model structure factor and 5% data omitted for Rfree.
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1222Figure 3. Cocrystal Structure of SpvB with NADH
(A) Alignments of SpvB with other ADP-ribosyltransferases based on minimizing the Ca positions of the core fold (SpvB yellow subdomain).
(B) Molecular surfaces of SpvB and the Bacillus cerus vegetative insecticidal protein (VIP2) colored by relative electrostatic potential (red, neg-
ative or acidic; blue, basic or positive). The insertion in SpvB is indicated. The cofactor is shown as a chemical model binding in the active site
pockets of the enzymes.
(C) Schematic of the contacts to NADH from SpvB. Solid, green bonds indicate the NADH molecule, and black bonds indicate residues from the
protein. Hydrogen bonds are shown as green, dashed lines between atoms (and the distance of the bond in angstroms is noted). van der Waals
contacts are shown in brown. Carbon, nitrogen, oxygen, and phosphorous atoms are shown in black, blue, red, and magneta, respectively.
Residues in SpvB are labeled and numbered.only marginal ribosylation in relation to wild-type when
treated with SpvB (Hochmann et al., 2006).
Despite the knowledge that Arg177 is targeted by this
broad family of toxins, now including SpvB, it is not well
understood how this modification prevents polymeriza-
tion. Previously, it has been shown that ADP-ribosylated
actin at Arg177 acts as a capping protein, capping the
barbed ends and impeding the addition of new actin
monomers, leading ultimately to inhibition of polymeri-
zation at substoichiometric ratios (Wegner and Aktories,
1988). ADPR-actin has no effect on the rate of polymer-
ization of gelsolin-capped actin filaments that polymer-
ize at the pointed ends, but it inhibits the polymerization
at the barbed ends, suggesting that it cannot bind to and
cap the pointed ends of the filaments (Wegner and Akto-
ries, 1988). Microinjection of Arg177 ADPR-actin caused
actin cytoskeletal disruption even in the absence of an
ATR, indicating that it is the modified actin alone that
confers the cytotoxic effects (Kiefer et al., 1996). How
these effects can be explained by the modification at
Arg177 has remained unresolved.
Two explanations for the effect of Arg177 ADP-ribosy-
lation, not mutually exclusive, appear likely: (1) that this
modification induces conformational changes in actin
not compatible with filament formation, and (2) that the
presence of ADPR at Arg177 causes a steric clash pre-
venting protein-protein interactions necessary for poly-merization. In order to differentiate between these pos-
sibilities, we determined the structure of actin that had
been ADP-ribosylated with SpvB (Table 2 and Experi-
mental Procedures). To date, all crystal structures of ac-
tin have been in the G form, either bound to proteins that
prevent polymerization (such as DNase I) or inhibited
pharmacologically from polymerizing, such as by the
drugs TMR (tetramethylrhodamine-5-maleimide) or la-
trunculin A (Bubb et al., 2002; Graceffa and Dominguez,
2003; Morton et al., 2000; Otterbein et al., 2001). The fil-
amentous forms of actin have resisted all attempts at
high-resolution structural determination. Crystallization
in the case of SpvB was feasible because SpvB-treated
actin is resistant to polymerization, even at the high pro-
tein concentrations required for crystallization. Two dif-
ferent crystal forms of actin, possessing very different
crystal packing arrangements, were obtained. In one,
actin crystallizes as a monomer in a hexagonal lattice,
whereas in the other, similar to what was seen in actin
crystals with latrunculin A and polylysine (Bubb et al.,
2002), two actin molecules form an antiparallel dimer
in the asymmetric unit in an orthorhombic lattice.
The three independent structures of actin in these two
crystal forms are very similar, and they align with rmsds
in Ca positions of less than 0.4 A˚ for all actin residues
(Figure 5A). The hexagonal structure aligns well to the
two orthorhombic molecules, but there is a slight
Structure of Salmonella SpvB and Modified Actin
1223Figure 4. Mass Spectrometric Analysis and Mapping of the ADPR Site
(A) Top panel: extracted mass chromatogram of the (M+3H)+3 ion for ADPR-modified peptides 148–183 in a control tryptic digest. Second panel:
extracted mass chromatogram of the (M+3H)+3 for ADPR-modified peptides 148–183 in a digest of ADPR-actin. Third panel: mass chromatogram
for the (M+4H)+4 ion for ADPR-modified peptides 148–183 in a tryptic digest of actin from crystals. Fourth panel: mass chromatogram for the
(M+3H)+3 ion for unmodified peptides 143–177 in actin from crystals.
(B) Partial mass spectra acquired by LC/FTMS for the (M+4H)+4 ions for ADPR-modified actin. Top panel: theory for C184H290N52O65P2S1. Middle
panel: acquired data for ADPR-actin. Bottom panel: acquired data for ADPR-modified actin from crystals. Note that all accurate mass data
matched theoretically to a < 2 ppm mass deviation.
(C) Spectrum acquired via LC/FTMSMS of the ADPR-modified actin tryptic digest showing daughter ions of 1092, verifying assignment as
(M+4H)+4 of ADP-modified peptides 148–183.
(D) Extracted mass chromatograms from LC/FT/MS analysis of the tryptic digest of nonmuscle actin for (M+4H)+4 of ADPR-modified peptides
148–183. Top panel: control. Bottom panel: modified actin.
(E) Partial mass spectrum from LC/FTMS of the tryptic digest of nonmuscle actin of (M+5H)+5. Top panel: theoretical (C184H291N51O65P2S1).
Bottom panel: acquired data.
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1224displacement in residues 55–68 (immediately after the
DNase I binding loop) and in residues 226–237. Between
the two copies of actin in the orthorhombic asymmetric
unit, there is a relative opening-closing hinge motion in
the nucleotide binding cleft of actin. In all three cases,
the DNase I binding loop (residues 39–51) is disordered,
and the nucleotide in the active site in all three structures
is the natural ligand, ATP (Figure 5B). The covalent mod-
ification, ADPR, is not visible in any of the electron den-
Table 2. ADPR-Actin Data Collection and Refinement Statistics
Hexagonal Orthorhombic
Data Collection
Space group P3221 P212121
Cell dimensions
a, b, c (A˚) 96.4, 96.4, 97.4 100.4, 102.3, 123.8
a, b, g () 90, 90, 120 90, 90, 120
Wavelength 0.979 0.979
Resolution (A˚) 99.0–1.90 40.0–2.00
Rsym (%) 4.6 (31.9) 4.2 (41.1)
I /sI 39.0 (6.0) 35.2 (3.00)
Completeness (%) 100.0 (100.0) 97.9 (99.2)
Refinement
Resolution (A˚) 83.3–1.90 78.8–2.00
Number of reflections 37,881 76,054
Rwork/Rfree (%) 15.2/18.4 17.1/21.0
Mean B factor 23.1 32.4
Rms deviations
Bond lengths (A˚) 0.020 0.019
Bond angles () 1.870 1.753
Rsym =
P
h
P
ijIh,i2 Ihj/
P
h
P
i Ih,i, for the intensity (I) of i observations
of reflection h. Values in parentheses are for the high-resolution
shell. R =
PjFP 2 Fcj/
P
FP; FP is the experimental structure factor,
and Fc is the model structure factor and 5% data omitted for Rfree.sity maps, suggesting that it is highly flexible and disor-
dered. Arg177 is not disordered, but its temperature
factors are somewhat higher than the average for the
protein (hexagonal crystal form: overall temperature fac-
tor = 18 A˚2; orthorhombic, dimeric, crystal form: overall
B =w30 A˚2), with the guanidinium group the highest of
all (hexagonal crystals temperature factor =w40 A˚2; or-
thorhombic =w60 A˚2). The crystal packing in both forms
is such that Arg177, and in fact the entire surface of actin
on which it is located, makes no crystal packing con-
tacts. The residue is solvated, providing ample space
for a flexible ADPR moiety.
The lack of interpretable density for the ADPR group
prompted us to examine the status of this modification
in the crystals. SpvB ADP-ribosylated actin was crystal-
lized, and the protein crystals were harvested, dis-
solved, and analyzed by mass spectrometry (Figure
4A, third and fourth panels). The results of this analysis
indicate the presence of components, of approximately
equal abundance, including residue Arg177 with and
without modification. This partial modification is likely
due to a hydrolysis of the modifying group during the 2
week period that was needed for crystal growth. The
peaks in the mass spectrometry are not quantitative be-
cause the two Arg177-containing peptides are different,
and it is difficult to ascertain the relative amounts of
modified and unmodified actin. Material analyzed imme-
diately after removal from cryogenic storage, however,
provides a single peak with the mass corresponding to
ADP-ribosylated actin. Since the crystals appear in a
day and require a few days for growth, it was technically
feasible to ‘‘trap’’ actin in a highly modified state in crys-
tals. However, hydrolysis does occur to a significant ex-
tent in the crystals, and it is favored by the high salt
concentration of the crystallization solution. Thus, partialFigure 5. Two Crystal Structures of ADP-
Ribosylated Actin
(A) Alignment of the three SpvB-ribosylated
actin models solved in this study: two from
the orthorhombic crystal form (blue and or-
ange), and the other from the hexagonal crys-
tal form (yellow).
(B) ATP and the calcium ion in the active site
of the hexagonal crystal form the actin struc-
ture, shown with a 2Fo 2 Fc difference elec-
tron density map contoured at 1.0s.
(C) Alignments of the hexagonal actin crystal
form structure with several other structures
of actin, including those from drug bound
and protein bound complexes.
(D) Table of the root-mean-square differ-
ences (rmsd) in actin Ca positions from the
alignments of SpvB-modified actin with those
of other crystallized structures of actin. The
rmsd is also similarly tabulated between the
hexagonal and orthorhombic crystal forms
of ADPR-actin from SpvB-treated material.
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1225Figure 6. Steric Clash Due to ADPR in the
Actin Helix
The Holmes model for the actin filament is
shown with the actin protomers differentially
colored. Arg177 is shown in blue in a space-
filling representation. Sequential magnifica-
tions of the helix are shown, and the final
magnification illustrates the putative Arg177
interaction residues Glu195, Ser199,
Phe200, and Val201. Superimposed on this
last image is the space-filling representation
of ADP-ribose (red) to illustrate its relative
size and emphasize the steric clash that
would occur were it conjugated to Arg177.occupancy, possibly in conjunction with disorder, likely
explains the inability to visualize this ADPR moiety.
Overall, the structures of actin obtained reveal that
there are no large-scale conformation alterations in actin
upon ribosylation by SpvB (Figure 5C), which argues
that such allosteric changes are not the primary cause
of polymerization deficiency induced by this modifica-
tion. The mixture of modified and unmodified actin in
the crystals discussed above likely does not invalidate
this conclusion. To begin, even if some fraction (less
than 50%, as judged by the relative peak heights) of
the actin in the crystalline form remains ADP-ribosy-
lated, the fact remains that all actin molecules in the
crystals have the same structure. It is unlikely that crys-
tal packing could accommodate two significantly differ-
ent structures for the two forms of actin. That we have
two completely different crystal forms of actin, with a to-
tal of three independent molecules of actin between
them, supports this conclusion. Were such discordant
crystal packing even to be the case, the low occupancy
of the ADP-ribosylated form would likely lead to ex-
tremely weak electron density for the differing polypep-
tide regions. The only place this could have reasonably
occurred, therefore, is the DNase I binding loop, which
is disordered. However, disorder in this region is the
norm for the ATP bound form of actin (Kudryashov and
Reisler, 2003).
Therefore, the model of a steric clash-induced hin-
drance of intraprotomer contacts in the filament likely
provides the best explanation for the activity of this vir-
ulence factor, and by extension, other bacterial toxins
that target Arg177 for ADP-ribosylation. In the filament
model of Holmes et al. (1990), Arg177 is proximal to
Glu195, Ser199, Phe200, and Val201 of a protomer in
the opposing strand of the filament, and it likely interacts
with these residues, leading to cross-strand stabiliza-
tion within the actin helix (Figure 6).
ADPR at Arg177 would lead to a dramatic steric clash
at the contact point between actin subunits and, there-
fore, to unfavorable protomer-protomer contacts (Fig-
ure 6). This is consistent with data showing that
Arg177 is expected to be completely buried upon the
formation of the Holmes model of actin, based on calcu-
lated solvent-accessible surface area (ASA) changes
upon the formation of F-actin and footprinting with hy-
droxyl radicals generated by synchrotron X-ray radioly-
sis (Guan, 2005). This is further supported by the finding
that a 2.6 kDa peptide of actin extending from Arg177 toTyr198 binds tightly to actin (Hori and Morita, 1992) and
by a large amount of mutagenesis showing that various
mutations in Arg177 lead to developmental deformities
in fish, cytoskeletal abnormalities in yeast, and in vitro
and in vivo impairment of actin nucleation and polymer-
ization (Drubin et al., 1993; Ng and Abelson, 1980; Schu-
ler et al., 2000; Wong et al., 2001).
Because of the extended time period required to grow
diffraction-quality crystals, the presence of ATP in the
active site of both crystal forms (indicating a lack of
ATP hydrolysis) suggested that ADP-ribosylation of ac-
tin by SpvB may inhibit the intrinsic ATPase activity of
actin, as has been observed in studies of actin modified
by other toxins. This indeed was found to be the case in
biochemical assays (Figure 7). An assay that measures
the release of inorganic phosphate from actin during
Figure 7. SpvB-Mediated ADP-Ribosylation Inhibits Phosphate
Release in Actin
The inorganic phosphate released continuously in solution by the in-
trinsic ATPase activity of actin was measured by an increase in ab-
sorbance (Experimental Procedures), shown in relative absorbance
units, for the ribosylated actin and for the control reaction containing
actin.
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phate release is decreased from ADP-ribosylated actin.
Arg177, conserved in all actin homologs, is considered
to be involved in the g-phosphate release from ATP, al-
though the precise mechanism is not well understood.
Molecular dynamics modeling suggested a ‘‘back-
door’’ mechanism in which the formation of a salt bridge
between MeHis73 (methylated histidine) and Asp184
creates a state of phosphate release and in which
Arg177 significantly retards the release of the phosphate
by interacting with it (Wriggers and Schulten, 1997,
1999).
Salmonella spp. utilize an arsenal of bacterial viru-
lence factors to modulate the host cell cytoskeleton
(Galan, 2001). Many of these, such as those of the
RhoGTPase family, indirectly do so by manipulating sig-
nal transduction cascades (Lilic and Stebbins, 2004;
Schlumberger and Hardt, 2005). Others directly modu-
late cytoskeletal structure by binding to and interacting
with cytoskeletal proteins such as actin and tubulin
(Gruenheid and Finlay, 2003; Stebbins, 2004). A large
number of these factors function in the initial stages of
infection through the SPI-1 pathogenicity island on the
bacterial chromosome by inducing actin polymerization,
leading to membrane ruffling and bacterial internaliza-
tion (Galan, 1999). The SPI-2 pathogenicity island func-
tions during later stages of infection, and it also interacts
with the host cytoskeleton to maintain the specialized
Salmonella-containing vacuole. SpvB inhibits actin
polymerization through mono-ADP-ribosylation of actin,
leading to apoptosis and potentially thereby contribut-
ing to bacterial spread to other professional phagocytes
upon autophagy (Guiney and Lesnick, 2005). Consistent
with this, SpvB is a critical element in systemic virulence
during infection with Salmonella.
We have shown that SpvB is a divergent ATR in that it
possesses, to our knowledge, novel elements in the fold.
However, its close similarities in the active site and co-
factor binding indicate that, as an enzyme, it likely func-
tions in a similar fashion to other actin-modifying ATRs
in targeting actin. Using mass spectrometry, we were
able to clearly establish that actin is ADP-ribosylated
at Arg177, the same residue of actin that is found to be
modified by several other ATR enzymes targeting this
cytoskeletal protein.
Few structures of actin are available due to its propen-
sity to polymerize. While structures of monomeric actin
in complex with proteins that sequester it from filament
formation or that are prevented from polymerizing
through pharmacological alteration exist, this report
presents, to our knowledge, the first structures of actin
that have been modified by a bacterial toxin. We have
found that the ADP-ribosylation of actin by SpvB at
Arg177 inhibits ATPase activity and likely prevents poly-
merization through a steric mechanism that involves
impeding critical protomer-protomer contacts required
for filament formation and stability. SpvB-treated and
-crystallized actin does not show any major confor-
mation alterations relative to other monomeric actin
structures, which therefore suggests that large-scale
conformational changes due to this modification likely
cannot explain the defect in polymerization. However,
an analysis of the protomer packing of actin in the fila-
ment indicates that the presence of ADPR at Arg177would lead to severe steric clash and likely to a disrup-
tion of the contacts modeled to hold the actin filament
together.
Experimental Procedures
Protein Purification and Domain Delineation of SpvB
SpvB (residues 370–591) was cloned by PCR from the Salmonella
typhimurium virulence plasmid and expressed in Escherichia coli
BL21(DE3) cells as N-terminal His6 fusion protein by using the
pET28 expression vector. The protein was purified by nickel ion affin-
ity chromatography and was then subjected to limited proteolysis
with subtilisin (Figure 1A). Fragments identified through N-terminal
sequencing and mass spectrometry were subcloned into the same
vector and purified as described above. A stable fragment spanning
residues 390–591 was active in actin ribosylation assays (Figure 1B)
and produced crystals. Selenomethionine-substituted protein was
prepared by following standard protocols (Doublie, 1997). Both,
wild-type (SpvB) and the selenomethionine (Se-SpvB) proteins
were purified to homogeneity by nickel ion affinity chromatography,
followed by the removal of the tag with thrombin, subtractive nickel
ion-Sepharose, and gel filtration chromatography on Superdex 75
(GE HealthCare). For crystallization, the purified SpvB and Se-SpvB
proteins were concentrated to 80 and 60 mg/ml, respectively, by ul-
trafiltration in 100 mM NaCl, 10 mM Tris-HCl (pH 8), and 2 mM DTT.
Actin Ribosylation
Actin (Cytoskeleton, Inc.) at 1–2 mg/ml in buffer containing 5 mM Tris
(pH 8.0), 0.2 mM ATP, 0.2 mM CaCl2, 2 mM DTT was mixed with
SpvB protein (100 mg), NAD (200 mM final concentration). After over-
night incubation at 4C, 100 mg SpvB protein and polymerization
buffer to a final concentration of 50 mM KCl, 2 mM MgCl2, 0.2 mM
ATP were added to this mixture, and the mixture was incubated at
room temperature for 2 hr. After incubation, the actin sample was
centrifuged at 100,000 3 g for 1 hr at 4C to separate G-actin, pre-
sumably ribosylated, from F-actin. The supernatant was purified fur-
ther on a HiLoad Superdex 75 gel filtration column in a buffer con-
taining 5 mM Tris (pH 8), 0.2 mM ATP, 0.2 mM CaCl2, 2 mM DTT,
and 100 mM NaCl. For crystallization, the ribosylated actin was con-
centrated at 15–30 mg/ml by ultrafiltration in buffer containing 5 mM
Tris (pH 8), 0.2 mM ATP, 0.2 mM CaCl2, and 2 mM DTT and was flash
frozen in liquid nitrogen for storage.
Protein Crystallization
SpvB and Se-SpvB crystals were obtained via hanging-drop vapor
diffusion against a reservoir solution consisting of 15% PEG 4000,
0.2 M Li2SO4, 100 mM Tris-HCl (pH 8.5), 4% sucrose, at 4
C, by using
a protein concentration of 20 mg/ml. Crystals of SpvB and Se-SpvB
grow spontaneously; however, their size and morphology were im-
proved dramatically by using microseeding. Crystal cryoprotection
was achieved by adding PEG 1000 in the crystallization drop to a final
concentration of 17.5% (v/v). Crystals diffracting to 1.5 A˚ (SpvB) and
2.0 A˚ resolution (Se-SpvB) grew in the hexagonal space group P3221
(a = b = 55.58 A˚, c = 143.57 A˚; a = b = 90, g = 120) with one molecule in
the asymmetric unit. All crystals appeared in 2–3 days and grew to
full size within 2–3 weeks. Crystals of SpvB-NADH were obtained
by soaking SpvB crystals overnight in the reservoir solution contain-
ing 1.5 mM NADH. SpvB-NADH crystals were cryoprotected by add-
ing PEG 1000 in the crystallization drop to a final concentration of
17.5% (v/v) as well as 5 mM NADH.
ADP-ribosyl-actin (ADPR-actin) crystals were obtained via hang-
ing-drop vapor diffusion against a reservoir solution consisting of
1.25 M (NH4)2SO4, 0.2 M Li2SO4, 50 mM Tris-HCl (pH 8.5) (hexagonal
form), or against a reservoir solution consisting of 1.1 M (NH4)2HPO4,
0.2 M NaCl, 100 mM citrate buffer (pH 5.5) (orthorhombic form), at
20C, by using a protein concentration of 10 mg/ml. Crystals of
ADPR-actin grew spontaneously in both conditions; however, their
size and morphology was improved by using microseeding. Crystal
cryoprotection was achieved by adding ethylene glycol in the crys-
tallization drop to a final concentration of 25% (v/v) for the hexagonal
form and glycerol to a final concentration of 25% (v/v) for the ortho-
rhombic form. Crystals diffracting to 1.7 A˚ resolution grew in the hex-
agonal space group P3221 (a = b = 96.36 A˚, c = 97.41 A˚; a = b = 90,
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solution. Crystals diffracting to 2.0 A˚ resolution grew in the ortho-
rhombic space group P212121 (a = 100.38 A˚, b = 102.34 A˚, c = 123.8
A˚; a = b = g = 90) with two molecules per asymmetric unit in the
phosphate solution.
Data Collection, Structure Determination, and Refinement
Diffraction data for all five structural determinations were measured
at beamlines X9A or X29 of the National Synchrotron Light Source at
Brookhaven National Laboratory. A single-wavelength anomalous
dispersion experiment (SAD) was conducted at an X-ray wavelength
near the selenium absorption peak with a single SpvB crystal at the
beamline X9A. Data were processed with the HKL software package
(Otwinowski and Minor, 1997). All four Se sites were found by using
SOLVE (Terwilliger, 1999; Terwilliger and Berendzen, 1999). The ex-
perimental phases were improved by density modification by using
RESOLVE (Terwilliger, 1999; Terwilliger and Berendzen, 1999), yield-
ing interpretable electron density maps of high quality to 2.0 A˚.
Roughly 85% of the protein main chain was built automatically by
this program. This partial structure was positioned in the native crys-
tal data set by molecular replacement with AMoRe (Navaza, 1994;
CCP4, 1994). ARP/wARP (Perrakis et al., 1999) was then used to
build and place the side chains of over 90% of the model and
ordered solvent, after which cycles of manual model building with
O (Jones et al., 1991) and refinement with REFMAC5 (Murshudov
et al., 1997) produced the final model with an R/Rfree of 15.6/20.3%
to 1.5 A˚. The structure of SpvB-NADH was determined by molecular
replacement by AMoRe by using the structure of SpvB. After rigid
body refinement, alternating cycles of simulated annealing, posi-
tional refinement, and model building were employed. Difference
electron density maps revealed unambiguous density for NADH
and allowed NADH placement. Several rounds of iterative model
building and refinement were performed by using O and REFMAC5,
producing a final model with an R/Rfree of 19.4/23.5% to 1.9 A˚.
The two actin structures were determined by molecular replace-
ment by using the structure of TMR-actin (Protein Data Bank entry
code 1J6Z). After rigid body refinement, alternating cycles of simu-
lated annealing with CNS (Brunger et al., 1998), positional refine-
ment, and model building were employed. Difference electron den-
sity maps revealed unambiguous density for ATP and allowed ATP
placement. Several rounds of iterative model building and refine-
ment were performed with O and REFAMC5, producing final models
with an R/Rfree of 15.2/18.4% to 1.7 A˚ for the hexagonal form and an
R/Rfree of 17.1/21.0% to 2.0 A˚ for the orthorhombic crystal form.
Residues 39–51 of the DNase I binding loop are not well resolved
in the electron density map and are presumed to be disordered.
All of the structures of SpvB and actin possess good stereochemis-
try, with over 90% of the residues in the most favored regions of the
Ramachandran plot, without outliers.
Actin Polymerization Assay
Pyrene G-actin (Cytoskeleton, Inc.) in buffer containing 5 mM Tris
(pH 8), 0.2 mM ATP, 0.2 mM CaCl2 was precleared by centrifugation
at 100,000 3 g before use. For the actin polymerization assay, pyr-
ene G-actin (10 mM) in buffer containing 5 mM Tris-HCl (pH 8.0),
0.2 mM CaCl2, 0.2 mM ATP was mixed with NAD (200 mM) and
with SpvB (2 mM) in buffer containing 10 mM Tris-HCl (pH 8.0), 100
mM NaCl, 2 mM DTT. The polymerization of G-actin was initiated
by the addition of polymerization buffer at a final concentration of
50 mM KCl, 2 mM MgCl2, 0.2 mM ATP. Fluorescence intensity was
subsequently measured on a fluorescence spectrophotometer
(SpectraMAX Gemini) with the excitation wavelength set to 365 nm
and the emission wavelength set to 407 nm. To determine the inhibi-
tion of SpvB activity by the mono-ADPR transferase-specific inhib-
itor, novobiocin, at a final concentration of 200 mM, was added to
the polymerization mixture containing SpvB and NAD. As a control,
polymerization reactions without SpvB were run in parallel.
Phosphate Release Assay
The inorganic phosphate released from F-actin during polymeriza-
tion was measured in a coupled assay by using the EnzChek
Phosphate Assay (Molecular Probes) for stopped-flow kinetic
experiment. The method consists of an enzymatic conversion of
the 2-amino-6-mercapto-7methyl-purine riboside (MESG) substrateto ribose 1-phosphate and 2-amino-6-mercapto-7methylpurine by
purine nucleoside phosphorylase (PNP) in the presence of Pi. The
conversion is accompanied by a change in absorption at 360 nm.
The assay was used to follow the kinetics of the Pi released contin-
uously by the ATPase activity of actin versus the ADP-ribosylated
actin. Briefly, 400 mg actin or SpvB-modified actin was incubated
with 1 unit of PNP enzyme, 200 mM MESG in 50 mM Tris (pH 7.5),
1 mM MgCl2, 0.01 sodium azide for 30 min at 22
C, and the absor-
bance at 360 nm was read as a function of time.
Mass Spectrometric Analysis of ADP-Ribosylated Actin
For intact molecular weight analysis, 5 ml of 2 mg/ml actin samples
were injected onto a 150 3 1 mm Jupiter C4 column (Phenomenex)
and eluted with a linear gradient with direct flow into a Micromass
Quattro Ultima mass spectrometer (Waters) operated under positive
ESI conditions. The acquired data were deconvoluted with MaxEnt1
to yield the mass of the protein. For the identification of the ADP-
ribosylation site, the ADP-ribosylated actin samples were digested
overnight with a 50:1 actin:trypsin ratio at 37C. The digested sam-
ples were analyzed by HPLC FTMS. The peptides (10 ml) were in-
jected onto a 1503 1 mm Hypersil C18 column (Thermo) and eluted
with a linear gradient with direct flow into a Bruker APEX Q T7 mass
spectrometer (Bruker Daltonics) operated under positive ESI mode.
External calibration with porcine rennin substrate provided better
than 5 ppm mass measurement accuracy (0.005 amu at m/z 1000).
The data were analyzed automatically with the Proqual program or
manually with MaxLynx (Waters). Proqual compares the molecular
weight of each tryptic fragment from the spectrum with a list of all
possible tryptic fragments of actin for the correct mass (within
5 ppm). Additionally, the data were searched for ADP-ribosylation
by adding the mass of 541 for this specific modification to each of
possible fragments.
Supplemental Data
Supplemental Data include the mass spectrometric analysis as well
as additional stereo figures and are available at http://www.
structure.org/cgi/content/full/14/8/1219/DC1/.
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